Engasertib Shows Promise for Recurrent Epistaxis in HHT: Proof‑of‑Concept Trial Demonstrates Reduced Bleeding with Acceptable Short‑Term Safety
Posted inHematology-Oncology news Otorhinolaryngology

Engasertib Shows Promise for Recurrent Epistaxis in HHT: Proof‑of‑Concept Trial Demonstrates Reduced Bleeding with Acceptable Short‑Term Safety

In a randomized, double‑blind, placebo‑controlled proof‑of‑concept trial, oral engasertib reduced epistaxis frequency and duration in hereditary hemorrhagic telangiectasia (HHT) with a safety profile similar to placebo except for reversible rash and occasional hyperglycemia.
One in Three Head and Neck Cancer Survivors Still Have Supportive Care Needs at Five Years — Fear of Recurrence and Pain Drive Long-Term Demand
Posted innews Oncology Otorhinolaryngology

One in Three Head and Neck Cancer Survivors Still Have Supportive Care Needs at Five Years — Fear of Recurrence and Pain Drive Long-Term Demand

Longitudinal data from 403 head and neck cancer survivors show that while information and health-system needs decline between years 2 and 5, one-third report at least one moderate-to-high unmet supportive care need at year 5—notably fatigue and dry mouth—with fear of cancer recurrence and ongoing analgesic use being the strongest correlates.
Half of Long‑Term Head and Neck Cancer Survivors Report Unmet Supportive Care Needs — A Multinational Cohort Highlights Clinical and System Drivers
Posted innews Oncology Otorhinolaryngology

Half of Long‑Term Head and Neck Cancer Survivors Report Unmet Supportive Care Needs — A Multinational Cohort Highlights Clinical and System Drivers

A multinational cross‑sectional study of 1,097 head and neck cancer survivors >5 years after diagnosis found that ~50% report moderate‑to‑high unmet supportive care needs, driven by HNC‑specific, psychological and physical/daily living concerns and associated with personal, clinical, lifestyle and health‑system factors.
Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer
Posted innews Oncology Otorhinolaryngology Pathology & Lab Medicine

Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer

In a multicenter cohort of 3,980 oral cavity squamous cell carcinoma patients, preoperative clinical and tumor features—including age, comorbidity, tumor subsite, size, clinical stage, and biopsy grade—predicted receipt and intensity of adjuvant therapy, with a predictive model AUC of 0.84.
Updated Basal Calcitonin Cutoffs Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer — Practical Thresholds for Surgery Planning
Posted innews Otorhinolaryngology

Updated Basal Calcitonin Cutoffs Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer — Practical Thresholds for Surgery Planning

A multicenter Chinese cohort of 509 initially treated MTC patients identifies new preoperative basal calcitonin thresholds (241.9, 693.9, 2378.5, 2787.1 pg/mL) that better predict central, ipsilateral lateral, bilateral/contralateral lateral, and upper mediastinal lymph node metastasis than older guideline cutoffs.
Updated Basal Calcitonin Cutoffs Better Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer
Posted inDiabetes & Endocrinology news Otorhinolaryngology

Updated Basal Calcitonin Cutoffs Better Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer

A multicenter Chinese cohort identifies new preoperative basal calcitonin thresholds (241.9, 693.9, 2378.5, 2787.1 pg/mL) that stratify risk of central, ipsilateral lateral, bilateral/contralateral lateral, and upper mediastinal lymph node metastasis and improve prediction of structural recurrence-free survival versus ATA guidance.
Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority
Posted innews Oncology Otorhinolaryngology

Proton Beam vs IMRT for Olfactory Neuroblastoma: Multicenter Propensity-Matched Cohort Shows No Clear Superiority

A multicenter propensity-matched cohort comparing adjuvant proton beam radiotherapy (PBRT) with intensity-modulated radiotherapy (IMRT) for olfactory neuroblastoma found no definitive differences in local control, recurrence-free survival, overall survival, or clinically meaningful reductions in grade ≥2 radiation toxicities, but estimates were imprecise.